A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome-Reference-Cited by-同舟云学术

A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome

Published:2014-06-23 Issue:9 Volume:89 Page:E156-E162
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Garcia-Manero Guillermo¹,Gartenberg Gary²,Steensma David P.³,Schipperus Martin R.⁴,Breems Dimitri A.⁵,de Paz Raquel⁶,Valcárcel David⁷,Kranenburg Britte⁸,Reddy Manjula⁹,Komrokji Rami S.¹⁰

Affiliation:

1. MD Anderson Cancer Center; University of Texas; Houston Texas

2. Janssen Research & Development; LLC; Raritan New Jersey

3. Dana-Farber Cancer Institute; Boston Massachusetts

4. Haga Teaching Hospital; The Hague The Netherlands

5. Hospital Network Antwerp; Campus Stuivenberg Antwerp Belgium

6. University Hospital La Paz; Madrid Spain

7. Hospital Vall d'Hebron, Universitat Autónoma de Barcelona; Barcelona Spain

8. Janssen Biologics Europe; Leiden The Netherlands

9. Janssen Research & Development; LLC; Spring House Pennsylvania

10. H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

Publisher